全文获取类型
收费全文 | 15255篇 |
免费 | 986篇 |
国内免费 | 88篇 |
专业分类
耳鼻咽喉 | 156篇 |
儿科学 | 285篇 |
妇产科学 | 258篇 |
基础医学 | 2068篇 |
口腔科学 | 162篇 |
临床医学 | 1349篇 |
内科学 | 3659篇 |
皮肤病学 | 270篇 |
神经病学 | 1615篇 |
特种医学 | 720篇 |
外科学 | 2669篇 |
综合类 | 33篇 |
一般理论 | 2篇 |
预防医学 | 677篇 |
眼科学 | 138篇 |
药学 | 1027篇 |
中国医学 | 19篇 |
肿瘤学 | 1222篇 |
出版年
2024年 | 9篇 |
2023年 | 102篇 |
2022年 | 164篇 |
2021年 | 472篇 |
2020年 | 224篇 |
2019年 | 458篇 |
2018年 | 538篇 |
2017年 | 358篇 |
2016年 | 361篇 |
2015年 | 444篇 |
2014年 | 691篇 |
2013年 | 806篇 |
2012年 | 1285篇 |
2011年 | 1318篇 |
2010年 | 733篇 |
2009年 | 706篇 |
2008年 | 1064篇 |
2007年 | 1008篇 |
2006年 | 1025篇 |
2005年 | 904篇 |
2004年 | 868篇 |
2003年 | 710篇 |
2002年 | 690篇 |
2001年 | 130篇 |
2000年 | 95篇 |
1999年 | 124篇 |
1998年 | 125篇 |
1997年 | 112篇 |
1996年 | 84篇 |
1995年 | 76篇 |
1994年 | 68篇 |
1993年 | 45篇 |
1992年 | 59篇 |
1991年 | 44篇 |
1990年 | 39篇 |
1989年 | 44篇 |
1988年 | 48篇 |
1987年 | 33篇 |
1986年 | 31篇 |
1985年 | 22篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 16篇 |
1978年 | 9篇 |
1975年 | 15篇 |
1974年 | 14篇 |
1972年 | 14篇 |
1971年 | 16篇 |
1970年 | 18篇 |
1969年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
161.
Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients
下载免费PDF全文
![点击此处可从《European journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jérôme Stirnemann Najett Kaddouri Medhi Khellaf Anne‐Sophie Morin Virginie Prendki Marc Michel Arsène Mekinian Philippe Bierling Pierre Fenaux Bertrand Godeau Olivier Fain 《European journal of haematology》2016,96(3):269-275
Although vincristine (VCR) is sometimes prescribed for newly diagnosed immune thrombocytopenia (ITP), its efficacy in refractory ITP and sustained efficacy has yet to be demonstrated. We describe our clinical experience and recommend vincristine's correct place in ITP management. This retrospective study analysed data from 35 patients with newly diagnosed (ND), persistent (P) or chronic (C) ITP treated with VCR. The initial response rate, defined as >30 × 109 platelets/L, reached 86% after a median of 7 [interquartile range (IQR) 6–13] days. In ND and P ITP, even when previous therapies were inefficient, initial response was 87.5%, suggesting that this treatment could be used particularly in rescue. Median survival time, without failure or relapse, was 15 months (Kaplan–Meier curve). Predictive factors (univariate analysis) of an initial and long‐term response were a small number of prior treatments received. However, at 2 yr, only seven patients had sustained response. Eight (23%) patients experienced adverse events: neuropathy for seven and bowel obstruction for one. Vincristine efficacy in ITP was confirmed, and it could be a good strategy for treating resistant ITP, especially in emergencies. In this era of new therapeutics, VCR deserves to remain on the list of ITP treatments because of its initial efficacy, safety and low cost. 相似文献
162.
Shreya Bhattacharya Olivier Duverger Stephen R. Brooks Maria I. Morasso 《Experimental dermatology》2018,27(3):289-292
Dlx4 is a member of a family of homeobox genes with homology to Drosophila distal‐less (dll) gene. We show that Dlx4 expression pattern partially overlaps with its cis‐linked gene Dlx3 during mouse development as well as in neonatal and adult skin. In mice, Dlx4 is expressed in the branchial arches, embryonic limbs, digits, nose, hair follicle and in the basal and suprabasal layers of mouse interfollicular epidermis. We show that inactivation of Dlx4 in mice did not result in any overtly gross pathology. Skin development, homeostasis and response to TPA treatment were similar in mice with loss of Dlx4 compared to wild‐type counterparts. 相似文献
163.
Macrolides have wide clinical applications in the treatment of community-acquired respiratory tract infections, among which streptococci are the most frequent causative agents. An active efflux-based mechanism of macrolide resistance, referred to as the M phenotype in streptococcal isolates, has been associated with the presence of mef genes that encode a subset of major facilitator superfamily (MFS) transporters like Mef(E). An msr(D) gene, adjacent to and co-transcribed with mef in the presence of erythromycin, has also been implicated in drug efflux, but its role remains elusive. Msr(D) belongs to the ATP binding cassette (ABC) proteins and harbors two fused nucleotide-binding domains with no membrane-spanning domains. The present work indicates that the major resistance traits of the M phenotype in Escherichia coli may be due to Msr(D) and not to Mef(E). Fluorescence microscopy using Mef(E) tagged with GFP linked low efficacy of the chimera in conferring macrolide resistance with improper subcellular localization. The active role of Msr(D) in directing Mef(E)-GFP to the cell poles was demonstrated, as was synergistic effect in terms of levels of resistance when both proteins were expressed. A trans-dominant negative mutation within ABC Msr(D) affecting MFS Mef(E) strongly suggests that both proteins can interact in vivo, and such a physical interaction was supported in vitro. This is the first reported example of a functional interplay between an ABC component and an MFS transporter. The direct involvement of Msr(D) in the efflux of macrolides remains to be demonstrated. 相似文献
164.
165.
166.
Tristeza disease (caused by citrus tristeza virus, CTV) is currently controlled in South Africa by means of cross-protection. In this study, we characterized the CTV populations of three grapefruit mild strain 12 (GFMS12) single-aphid-transmission-derived sub-isolates at the whole-genome level using Illumina sequencing technology. A novel South African isolate (CT-ZA3, of the T68 genotype) was shown to be the dominant genotype in all GFMS12 sub-isolates tested, along with reads unique to various other genotypes occurring as minor components. Uncertainty remains as to the significance of these minor components. 相似文献
167.
168.
Anne-Esther Breyton Aurélie Goux Stéphanie Lambert-Porcheron Alexandra Meynier Monique Sothier Laurie VanDenBerghe Olivier Brack Emmanuel Disse Martine Laville Sophie Vinoy Julie-Anne Nazare 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(1):237-246
Background and aimsIn type 2 diabetes (T2D) patients, the reduction of glycemic variability and postprandial glucose excursions is essential to limit diabetes complications, beyond HbA1c level. This study aimed at determining whether increasing the content of Slowly Digestible Starch (SDS) in T2D patients’ diet could reduce postprandial hyperglycemia and glycemic variability compared with a conventional low-SDS diet.Methods and resultsFor this randomized cross-over pilot study, 8 subjects with T2D consumed a controlled diet for one week, containing starchy products high or low in SDS. Glycemic variability parameters were evaluated using a Continuous Glucose Monitoring System.Glycemic variability was significantly lower during High-SDS diet compared to Low-SDS diet for MAGE (Mean Amplitude of Glycemic Excursions, p < 0.01), SD (Standard Deviation, p < 0.05), and CV (Coefficient of Variation, p < 0.01). The TIR (Time In Range) [140–180 mg/dL[ was significantly higher during High-SDS diet (p < 0.0001) whereas TIRs ≥180 mg/dL were significantly lower during High-SDS diet. Post-meals tAUC (total Area Under the Curve) were significantly lower during High-SDS diet.ConclusionOne week of High-SDS Diet in T2D patients significantly improves glycemic variability and reduces postprandial glycemic excursions. Modulation of starch digestibility in the diet could be used as a simple nutritional tool in T2D patients to improve daily glycemic control.Registration numberin clinicaltrials.gov: NCT 03289494. 相似文献
169.
170.